Increasing

the odds

Giving everyone diagnosed with cancer, their best chance to become cancer free.

27%

Studies in colorectal cancer have shown that up to 27% of patients¹ with early stage disease have previously undetected micro-metastases.

This can lead to inaccurate diagnosis and disease recurrence. Ferronova has developed a surgical oncology tracer system that aims to improve the staging of complex cancers and help increase survival rates.

The gap

More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate staging of how far, and where cancer has spread from a primary tumour. Current technologies and methods are not able to reliably detect small tumours in lymph nodes

Our solution

Our unique IP technology is a new-generation, polymer-coated magnetic nanoparticle.

This nanoparticle drives a magnetically guided imaging system designed to precisely identify sentinel lymph nodes, to assist surgeons and pathologists to more accurately stage solid tumours and locate and address micro-metastases that may otherwise go undetected

The future of cancer

imaging and surgery

Generate a clear roadmap of the lymphatic system for precise surgical lymph node sampling

Facilitate accurate identification of true sentinel nodes

Enable detection of micro-metastases that would otherwise be missed

Colorectal cancers

The magnetic technology is well suited to complex cancers, where resolution and the ability to locate sentinel lymph nodes close to the injection site are critical.

Our roadmap

May 2016

2020-2022

2023+

Ferronova Incorporated

Feasibility Trials

Pivotal Trials

Our roadmap

May 2016

Ferronova Incorporated

2020-2022

Feasibility Trials

2023+

Pivotal Trials

Clinical trials

Ferronova’s patented polymer-coated iron oxide nanoparticles, made to global standards at a facility in Mawson Lakes, has begun trial at the Royal Adelaide Hospital and Royal Melbourne (Peter MacCallum). 

1. Protic M et al. J Am Coll Surg 2015;221(3):643-51.